Literature DB >> 22454490

Interleukin-6 and C-reactive protein levels after 3 years of treatment with darunavir/ritonavir monotherapy or darunavir/ritonavir + two nucleoside reverse transcriptase inhibitors in the MONET trial.

Jose Arribas, Andrew Hill, Ning Xi, Yvon van Delft, Christiane Moecklinghoff.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22454490     DOI： 10.1093/jac/dks102

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  3 in total

Review 1.  Dual Antiretroviral Therapy-All Quiet Beneath the Surface?

Authors:  Berend J van Welzen; Patrick G A Oomen; Andy I M Hoepelman
Journal:  Front Immunol       Date:  2021-02-12       Impact factor: 7.561

2.  Inflammatory, procoagulant markers and HIV residual viremia in patients receiving protease inhibitor monotherapy or triple drug therapy: a cross-sectional study.

Authors:  Miriam Estébanez; Natalia Stella-Ascariz; Jesús Mingorance; Ignacio Pérez-Valero; Jose Ignacio Bernardino; Francisco Xavier Zamora; Maria Luisa Montes; Juan Julián González-García; José Ramón Arribas
Journal:  BMC Infect Dis       Date:  2014-07-10       Impact factor: 3.090

3.  Protease inhibitor monotherapy is associated with a higher level of monocyte activation, bacterial translocation and inflammation.

Authors:  Berta Torres; Alberto C Guardo; Lorna Leal; Agathe Leon; Constanza Lucero; Míriam J Alvarez-Martinez; Miguel J Martinez; Jordi Vila; María Martínez-Rebollar; Ana González-Cordón; Josep M Gatell; Montserrat Plana; Felipe García
Journal:  J Int AIDS Soc       Date:  2014-09-29       Impact factor: 5.396
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.